DiaMedica's DM199 shows promise for Acute Ischemic Stroke, but caution is advised due to low market cap and trial outcome uncertainties. See more on DMAC here.

Bioxyne lifts revenue 77% QoQ; Radiopharm listed on the Nasdaq in the December quarter; Tryptomine hits key milestones; Quarterly season is nearing its end, triggering a rush from ...

Several ASX-listed companies are undertaking phase III clinical trials, the critical final stage before potential regulatory ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), a commercial-stage biopharmaceutical company with a "GOOD" InvestingPro Financial ...

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

Solid Biosciences Inc. (NASDAQ:SLDB), a biotechnology company with a market capitalization of $133 million, recently reported that Ilan Ganot, a director at the company, engaged in stock transactions ...

Carlsbad-based Tyra Biosciences , Inc. announced a change in its Board of Directors, according to a recent SEC filing. On ...

We recently published a list of 10 Unstoppable Stocks to Buy in 2025. In this article, we are going to take a look at where ...

Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.

Oppenheimer made a significant adjustment to Zentalis Pharmaceuticals' (NASDAQ:ZNTL) price target, reducing it from $20.00 to ...

As per the recent earnings update by FactSet dated 24th January 2025, the Q4 2024 earnings season for the S&P 500 has seen a ...